Recombinant factor VIIa - rEVO Biologics/LFB

Drug Profile

Recombinant factor VIIa - rEVO Biologics/LFB

Alternative Names: COAGULATION FACTOR VIIA RECOMBINANT - rEVO Biologics/LFB; EPTACOG BETA ACTIVATED; LR 769; rhFVIIa

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer HEMA Biologics; LFB Biotechnologies; rEVO Biologics
  • Class Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia A; Haemophilia B

Most Recent Events

  • 09 Jan 2017 Preregistration for Haemophilia A and Haemophilia B (In adolescents, In adults, In children, In infants) in USA (Parenteral)
  • 09 Jan 2017 Efficacy and adverse events data from the phase III PERSEPT 1 trial in Hemophilia A and B released by LFB Biotechnologies
  • 06 Jan 2017 HEMA Biologics has full commercialisation rights for recombinant factor VIIa in North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top